The arena of multiple sclerosis (MS) treatment has changed substantially over the past 20 years. Now nine different agents are approved for use in MS with several different routes of administration, safety characteristics and efficacy profiles.
For the clinician and patient the availability of agents means greater flexibility and chances of disease control. However the expansion of options has also made the treatment of MS an increasingly complex field.
This book is intended to help the general neurologist, internist and pharmaceutical industry agent to quickly become familiar with the current and future options for treating relapsing forms of MS.
Multiple Sclerosis
| Pubblication date | October 2013 |
|---|---|
| Language | |
| Format | 12 × 17 cm |
| Number pages | 150 |
| ISBN | 978-88-9741-947-1 |
| ISBN e-book | 978-88-9741-948-8
Buy our ebooks in the main online stores
Buy ebook
|
The arena of multiple sclerosis (MS) treatment has changed substantially over the past 20 years. Now nine different agents are approved for use in MS with several different routes of administration, safety characteristics and efficacy profiles.
For the clinician and patient the availability of agents means greater flexibility and chances of disease control. However the expansion of options has also made the treatment of MS an increasingly complex field.
This book is intended to help the general neurologist, internist and pharmaceutical industry agent to quickly become familiar with the current and future options for treating relapsing forms of MS.
Target
Internists, neurologists, personnel of pharmaceutical industry.
15,00€
Daniel Ontaneda
| Pubblication date | October 2013 |
|---|---|
| Language | |
| Format | 12 × 17 cm |
| Number pages | 150 |
| ISBN | 978-88-9741-947-1 |
| ISBN e-book | 978-88-9741-948-8
Buy our ebooks in the main online stores
Buy ebook
|
Summary
Introduction
- Scope
- Overview of multiple sclerosis
Disease modifying agents for multiple sclerosis
- Interferon for MS
- Glatiramer acetate for MS
- Mitoxantrone for MS
- Natalizumab for MS
- Fingolimod for MS
- Teriflunomide for MS
- Dimethyl fumarate for MS
Treatment of relapses
- Defining relapses
- Treatment of MS relapses
Emerging therapies for multiple sclerosis
- Laquinimod for MS
- Alemtuzumab for MS
- Daclizumab for MS
- Ocrelizumab and rituximab for MS
